Hargreave Hale AIM VCT
88 Wood Street, London, England, EC2V 7QR, United Kingdom
Overview
Established in 1897, Hargreave Hale remains a private company that has evolved into a leading fund manager and provider of investment management and stockbroking services to individuals, families, corporate entities, charities, trusts, solicitors, accountants and intermediaries. As of January 2016, Hargreave Hale has more than 200 employees spread across 9 offices in the United Kingdom, including 14 members of its fund management team. Hargreave Hale mandates includes: Marlborough Multi-Cap Income Fund Marlborough Multi-Cap Growth Fund Marlborough Multi-Cap European Fund Marlborough Special Situations Fund Marlborough UK Micro-Cap Growth Fund Marlborough UK Nano-Cap Fund Marlborough Extra Income Fund Hargreave Hale AIM VCT 1 plc Hargreave Hale AIM VCT 2 plc.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 1
Sector focus
- Asset Management
Investment portfolio
- Qureight
Participated · Series B · Jul 2026
Qureight provides two integrated products for pharmaceutical clinical trials: Workflow, which speeds imaging decision turnaround from about two weeks to 48 hours, and AI Lung, which constructs detailed models of airways and blood vessels from chest scans. The company has built a general-purpose foundation model of the chest that enables development of disease-specific deep learning models in one to two months. Qureight is running global clinical trials with partners including AstraZeneca, Bristol Myers Squibb, and several biotech firms. Founded in 2018, the company combines clinical leadership—co-founder and CEO Dr Muhunthan Thillai continues clinical work—with a senior technical team recruited from industry and academia. Financially, Qureight has raised a £1.5 million seed in 2022 and the recent $20 million Series B to support lab build-out, therapeutic-area expansion, and headcount growth.
Team
Anna Salim
LinkedIn